Eli Lilly
Sells tirzepatide and the oral GLP-1 pill orforglipron and is testing retatrutide and eloralintide for obesity and diabetes.
Share price
$1,179
Up 41% over 12 monthsWhat analysts expect
Buy
Buy85%
Hold10%
Sell5%
Price target for the next 12 months
$1,310Up 5.9% compared with the current price
Price now $1,240Average targetLowest $900 to highest $1,600
29 analysts. Source: MarketBeat, 20 Oct 2026. Targets are opinions and are often wrong.
Business
- Yearly revenue
- $80B
- Yearly profit
- $27B
- Company value
- $1.1T
Revenue and profit for the last twelve months reported.
Peptides in this book
- TirzepatidePrescription
- OrforglipronPrescription
- RetatrutideTrials only
- EloralintideTrials only
- MazdutideTrials only
- TeriparatidePrescription
Recent news
- 2026-09-30 Retatrutide shows large weight and A1C reductions in TRIUMPH-2 diabetes trial PR Newswire
- 2026-10-01 Eloralintide plus tirzepatide beats tirzepatide alone on weight loss in mid-stage trial Reuters
- 2026-10-01 Orforglipron shows cardiovascular safety in its largest type 2 diabetes study PR Newswire
Risk in the news: MarketWatch reported more side effects when eloralintide was added to Zepbound.
Prices are delayed and figures rounded. Not investment advice.